| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| J J Holst, C F Deaco. Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes. Diabetes. vol 47. issue 11. 1998-11-10. PMID:9792533. |
glp-1 has multifaceted actions, which include stimulation of insulin gene expression, trophic effects on the beta-cells, inhibition of glucagon secretion, promotion of satiety, inhibition of food intake, and slowing of gastric emptying, all of which contribute to normalizing elevated glucose levels. |
1998-11-10 |
2023-08-12 |
Not clear |
| V Serre, W Dolci, E Schaerer, L Scrocchi, D Drucker, S Efrat, B Thoren. Exendin-(9-39) is an inverse agonist of the murine glucagon-like peptide-1 receptor: implications for basal intracellular cyclic adenosine 3',5'-monophosphate levels and beta-cell glucose competence. Endocrinology. vol 139. issue 11. 1998-11-06. PMID:9794451. |
the effect of exendin-(9-39), a described antagonist of the glucagon-like peptide-1 (glp-1) receptor, was evaluated on the formation of camp- and glucose-stimulated insulin secretion (gsis) by the conditionally immortalized murine betatc-tet cells. |
1998-11-06 |
2023-08-12 |
mouse |
| V Serre, W Dolci, E Schaerer, L Scrocchi, D Drucker, S Efrat, B Thoren. Exendin-(9-39) is an inverse agonist of the murine glucagon-like peptide-1 receptor: implications for basal intracellular cyclic adenosine 3',5'-monophosphate levels and beta-cell glucose competence. Endocrinology. vol 139. issue 11. 1998-11-06. PMID:9794451. |
these data therefore demonstrated that 1) exendin-(9-39) is an inverse agonist of the murine glp-1 receptor; 2) the decreased basal camp levels induced by this peptide inhibit the secretory response of betatc-tet cells and mouse pancreatic islets to glucose; 3) as this effect was observed only with growth-arrested cells, this indicates that the mechanism by which camp leads to potentiation of insulin secretion is different in proliferating and growth-arrested cells; and 4) the presence of the glp-1 receptor, even in the absence of bound peptide, is important for maintaining elevated intracellular camp levels and, therefore, the glucose competence of the beta-cells. |
1998-11-06 |
2023-08-12 |
mouse |
| E Ferrannin. Insulin resistance versus insulin deficiency in non-insulin-dependent diabetes mellitus: problems and prospects. Endocrine reviews. vol 19. issue 4. 1998-10-29. PMID:9715376. |
incidentally, any defect in insulin secretion, whether in normoglycemic or hyperglycemic persons, could be due to other factors than primary beta-cell dysfunction: amyloid deposits in the pancreas (126), changes in insulin secretagogues (amylin, glp-1, gip, galanin) (127-130), early intrauterine malnutrition (131). |
1998-10-29 |
2023-08-12 |
human |
| H Q Shen, M D Roth, R G Peterso. The effect of glucose and glucagon-like peptide-1 stimulation on insulin release in the perfused pancreas in a non-insulin-dependent diabetes mellitus animal model. Metabolism: clinical and experimental. vol 47. issue 9. 1998-10-08. PMID:9751230. |
pancreas perfusion and enzyme-linked immunosorbent assay (elisa) were used to detect the changes in insulin release under fasting and hyperglycemic conditions and following stimulation with glp-1. |
1998-10-08 |
2023-08-12 |
rat |
| H Q Shen, M D Roth, R G Peterso. The effect of glucose and glucagon-like peptide-1 stimulation on insulin release in the perfused pancreas in a non-insulin-dependent diabetes mellitus animal model. Metabolism: clinical and experimental. vol 47. issue 9. 1998-10-08. PMID:9751230. |
glucose plus glp-1 stimulation caused increased insulin release in all groups. |
1998-10-08 |
2023-08-12 |
rat |
| H Q Shen, M D Roth, R G Peterso. The effect of glucose and glucagon-like peptide-1 stimulation on insulin release in the perfused pancreas in a non-insulin-dependent diabetes mellitus animal model. Metabolism: clinical and experimental. vol 47. issue 9. 1998-10-08. PMID:9751230. |
these results support the hypothesis that glp-1 can effectively stimulate insulin secretion. |
1998-10-08 |
2023-08-12 |
rat |
| H Q Shen, M D Roth, R G Peterso. The effect of glucose and glucagon-like peptide-1 stimulation on insulin release in the perfused pancreas in a non-insulin-dependent diabetes mellitus animal model. Metabolism: clinical and experimental. vol 47. issue 9. 1998-10-08. PMID:9751230. |
insulin release was defective in zdf obese rats and could be partially restored with glp-1. |
1998-10-08 |
2023-08-12 |
rat |
| H Q Shen, M D Roth, R G Peterso. The effect of glucose and glucagon-like peptide-1 stimulation on insulin release in the perfused pancreas in a non-insulin-dependent diabetes mellitus animal model. Metabolism: clinical and experimental. vol 47. issue 9. 1998-10-08. PMID:9751230. |
this study documents the efficacy of glp-1 to stimulate insulin release and contributes to our understanding of the pathophysiological mechanisms underlying niddm. |
1998-10-08 |
2023-08-12 |
rat |
| P L Brubaker, J Schloos, D J Drucke. Regulation of glucagon-like peptide-1 synthesis and secretion in the GLUTag enteroendocrine cell line. Endocrinology. vol 139. issue 10. 1998-10-08. PMID:9751489. |
glucagon-like peptide-1 (glp-1) released from the intestine is a potent stimulator of glucose-dependent insulin secretion. |
1998-10-08 |
2023-08-12 |
Not clear |
| E Näslund, M Gutniak, S Skogar, S Rössner, P M Hellströ. Glucagon-like peptide 1 increases the period of postprandial satiety and slows gastric emptying in obese men. The American journal of clinical nutrition. vol 68. issue 3. 1998-09-29. PMID:9734726. |
postprandial blood glucose concentrations were reduced during the glp-1 infusion, but the amount of energy consumed, eating rate, and plasma concentrations of insulin, glucagon, and c-peptide were unchanged. |
1998-09-29 |
2023-08-12 |
human |
| J H Lavin, G A Wittert, J Andrews, B Yeap, J M Wishart, H A Morris, J E Morley, M Horowitz, N W Rea. Interaction of insulin, glucagon-like peptide 1, gastric inhibitory polypeptide, and appetite in response to intraduodenal carbohydrate. The American journal of clinical nutrition. vol 68. issue 3. 1998-09-29. PMID:9734735. |
insulin, gastric inhibitory polypeptide (gip), glucagon-like peptide 1 (glp-1), and appetite ratings were measured during, and food intake was measured after, intraduodenal infusions of glucose or saline. |
1998-09-29 |
2023-08-12 |
human |
| J H Lavin, G A Wittert, J Andrews, B Yeap, J M Wishart, H A Morris, J E Morley, M Horowitz, N W Rea. Interaction of insulin, glucagon-like peptide 1, gastric inhibitory polypeptide, and appetite in response to intraduodenal carbohydrate. The American journal of clinical nutrition. vol 68. issue 3. 1998-09-29. PMID:9734735. |
raising plasma insulin with intravenous insulin infusion to concentrations slightly above usual postprandial concentrations (356.4 +/- 4.8 pmol/l) had no effect on gip, glp-1, or appetite ratings before the intraduodenal infusions began. |
1998-09-29 |
2023-08-12 |
human |
| J H Lavin, G A Wittert, J Andrews, B Yeap, J M Wishart, H A Morris, J E Morley, M Horowitz, N W Rea. Interaction of insulin, glucagon-like peptide 1, gastric inhibitory polypeptide, and appetite in response to intraduodenal carbohydrate. The American journal of clinical nutrition. vol 68. issue 3. 1998-09-29. PMID:9734735. |
intraduodenal glucose infusion resulted in a further increase in plasma insulin to a peak of 779.4 +/- 114.0 pmol/l, caused an early increase in plasma gip and a later increase in glp-1 concentrations (p < 0.01), suppressed appetite (p < 0.05), and reduced energy intake (p < 0.01) compared with intraduodenal infusion of saline. |
1998-09-29 |
2023-08-12 |
human |
| J H Lavin, G A Wittert, J Andrews, B Yeap, J M Wishart, H A Morris, J E Morley, M Horowitz, N W Rea. Interaction of insulin, glucagon-like peptide 1, gastric inhibitory polypeptide, and appetite in response to intraduodenal carbohydrate. The American journal of clinical nutrition. vol 68. issue 3. 1998-09-29. PMID:9734735. |
infusion of octreotide to suppress the release of gastrointestinal hormones prevented the rise in insulin, gip, and glp-1 induced by intraduodenal glucose infusion and reversed the suppression of appetite and reduction in energy intake. |
1998-09-29 |
2023-08-12 |
human |
| J H Lavin, G A Wittert, J Andrews, B Yeap, J M Wishart, H A Morris, J E Morley, M Horowitz, N W Rea. Interaction of insulin, glucagon-like peptide 1, gastric inhibitory polypeptide, and appetite in response to intraduodenal carbohydrate. The American journal of clinical nutrition. vol 68. issue 3. 1998-09-29. PMID:9734735. |
these results suggest that 1) when infused to result in plasma concentrations slightly above usual postprandial concentrations, insulin does not inhibit its own release and 2) the effects of intraduodenal glucose on appetite may be mediated through the release of glp-1 and not insulin. |
1998-09-29 |
2023-08-12 |
human |
| T Tolessa, M Gutniak, J J Holst, S Efendic, P M Hellströ. Inhibitory effect of glucagon-like peptide-1 on small bowel motility. Fasting but not fed motility inhibited via nitric oxide independently of insulin and somatostatin. The Journal of clinical investigation. vol 102. issue 4. 1998-09-16. PMID:9710445. |
effects of glucagon-like peptide-1 (glp-1)(7-36)amide on fasted and fed motility in the rat small intestine were investigated in relation to its dependence on nitric oxide (no), insulin, and somatostatin. |
1998-09-16 |
2023-08-12 |
rat |
| T Tolessa, M Gutniak, J J Holst, S Efendic, P M Hellströ. Inhibitory effect of glucagon-like peptide-1 on small bowel motility. Fasting but not fed motility inhibited via nitric oxide independently of insulin and somatostatin. The Journal of clinical investigation. vol 102. issue 4. 1998-09-16. PMID:9710445. |
infusion of glp-1 (20-100 pmol kg-1min-1) did not affect plasma insulin, but somatostatin was increased. |
1998-09-16 |
2023-08-12 |
rat |
| B Willms, K Idowu, J J Holst, W Creutzfeldt, M A Nauc. Overnight GLP-1 normalizes fasting but not daytime plasma glucose levels in NIDDM patients. Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association. vol 106. issue 2. 1998-09-10. PMID:9628239. |
thereafter, starting 1 h after breakfast, no significant differences in plasma glucose, insulin, c-peptide or glucagon profiles were found between experiments with glp-1 (7-36 amide) and placebo. |
1998-09-10 |
2023-08-12 |
human |
| B Willms, K Idowu, J J Holst, W Creutzfeldt, M A Nauc. Overnight GLP-1 normalizes fasting but not daytime plasma glucose levels in NIDDM patients. Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association. vol 106. issue 2. 1998-09-10. PMID:9628239. |
in conclusion, (1) overnight glp-1 (7-36 amide) normalizes fasting plasma glucose, but (2) has no sustained effect on meal-induced glucose, insulin or glucagon concentrations once its administration has been stopped. |
1998-09-10 |
2023-08-12 |
human |